CFDE Data Portal | Search TEX14BP

	Label	Description
	TEX14BP Gene (Entity type)	ENSG00000293484 - testis expressed 14B, pseudogene
	GSE114883 romidepsin T cell 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE217552 fisetin 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207499 sphingosine 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE189859 GSE189861 IDH1 knockout 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 8 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE126651 PRMT5 MTAP inhibition 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

TEX14BP

ENSG00000293484 - testis expressed 14B, pseudogene

GSE114883 romidepsin T cell 1 v 2 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE114883 romidepsin T cell 0 v 2 human up

A Gene Set from LINCS

GSE217552 fisetin 3 v 2 human up

A Gene Set from LINCS

GSE207499 sphingosine 1 v 0 human up

A Gene Set from LINCS

GSE189859 GSE189861 IDH1 knockout 0 v 2 human up

A Gene Set from LINCS

GSE195568 palbociclib 2 v 4 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 8 v 5 human dn

A Gene Set from LINCS

GSE126651 PRMT5 MTAP inhibition 1 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.